Haemophilus Influenzae type b Vaccines: Current Trends and Future Outlook: The evaluation of the efficacy of Haemophilus influenzae type b vaccines and the potential strategies for Nontypeable Haemophilus influenzae vaccines.

Jian Kim

doi:10.58445/rars.1522

##article.authors##

Jian Kim none

DOI:

https://doi.org/10.58445/rars.1522

Keywords:

vaccines, biology, immunology, Biomolecules

Abstract

More than 10 million children under the age of 5 die annually due to Haemophilus influenzae type b (Hib), and it can be concluded that infants and children are patient groups at particular risk. Among Hib, certain serotypes such as Nontypeable Haemophilus Influenzae (NTHi) are particularly difficult to treat as they are harder to detect and have high mutation rate as they spread from the nasopharyngeal. Despite the success of current Hib vaccines, vaccine candidates against NTHi continue to be a challenge as the current conjugate vaccines do not work effectively against the nontypeable strains. By examining the effectiveness of existing vaccines, this review article emphasizes the need for continued research to expand vaccine development for both typeable and nontypeable strains of Hib to mitigate the Hib-related diseases.

References

(1) Khattak, Z. E.; Anjum, F. Haemophilus Influenzae Infection. In StatPearls; StatPearls Publishing: Treasure Island (FL), 2023.

(2) Mäkelä, P. H. Unencapsulated Haemophilus Influenzae--What Kind of Pathogen? Eur J Clin Microbiol Infect Dis 1988, 7 (5), 606–609. https://doi.org/10.1007/BF01964236.

(3) Bröker, M. Burden of Invasive Disease Caused by Haemophilus Influenzae Type b (Hib) in Africa. Minerva Pediatr 2008, 60 (3), 337–342.

(4) Slack, M. P. E. A Review of the Role of Haemophilus Influenzae in Community-Acquired Pneumonia. Pneumonia (Nathan) 2015, 6, 26–43. https://doi.org/10.15172/pneu.2015.6/520.

(5) Murphy, T. F.; Faden, H.; Bakaletz, L. O.; Kyd, J. M.; Forsgren, A.; Campos, J.; Virji, M.; Pelton, S. I. Nontypeable Haemophilus Influenzae as a Pathogen in Children. Pediatr Infect Dis J 2009, 28 (1), 43–48. https://doi.org/10.1097/INF.0b013e318184dba2.

(6) Levine, O. S.; Lagos, R.; Muñoz, A.; Villaroel, J.; Alvarez, A. M.; Abrego, P.; Levine, M. M. Defining the Burden of Pneumonia in Children Preventable by Vaccination against Haemophilus Influenzae Type b. Pediatr Infect Dis J 1999, 18 (12), 1060–1064. https://doi.org/10.1097/00006454-199912000-00006.

(7) Doherty, M.; Buchy, P.; Standaert, B.; Giaquinto, C.; Prado-Cohrs, D. Vaccine Impact: Benefits for Human Health. Vaccine 2016, 34 (52), 6707–6714. https://doi.org/10.1016/j.vaccine.2016.10.025.

(8) Nandi, A.; Shet, A. Why Vaccines Matter: Understanding the Broader Health, Economic, and Child Development Benefits of Routine Vaccination. Hum Vaccin Immunother 2020, 16 (8), 1900–1904. https://doi.org/10.1080/21645515.2019.1708669.

(9) Brueggemann, A. B.; Jansen van Rensburg, M. J.; Shaw, D.; McCarthy, N. D.; Jolley, K. A.; Maiden, M. C. J.; van der Linden, M. P. G.; Amin-Chowdhury, Z.; Bennett, D. E.; Borrow, R.; Brandileone, M.-C. C.; Broughton, K.; Campbell, R.; Cao, B.; Casanova, C.; Choi, E. H.; Chu, Y. W.; Clark, S. A.; Claus, H.; Coelho, J.; Corcoran, M.; Cottrell, S.; Cunney, R. J.; Dalby, T.; Davies, H.; de Gouveia, L.; Deghmane, A.-E.; Demczuk, W.; Desmet, S.; Drew, R. J.; du Plessis, M.; Erlendsdottir, H.; Fry, N. K.; Fuursted, K.; Gray, S. J.; Henriques-Normark, B.; Hale, T.; Hilty, M.; Hoffmann, S.; Humphreys, H.; Ip, M.; Jacobsson, S.; Johnston, J.; Kozakova, J.; Kristinsson, K. G.; Krizova, P.; Kuch, A.; Ladhani, S. N.; Lâm, T.-T.; Lebedova, V.; Lindholm, L.; Litt, D. J.; Martin, I.; Martiny, D.; Mattheus, W.; McElligott, M.; Meehan, M.; Meiring, S.; Mölling, P.; Morfeldt, E.; Morgan, J.; Mulhall, R. M.; Muñoz-Almagro, C.; Murdoch, D. R.; Murphy, J.; Musilek, M.; Mzabi, A.; Perez-Argüello, A.; Perrin, M.; Perry, M.; Redin, A.; Roberts, R.; Roberts, M.; Rokney, A.; Ron, M.; Scott, K. J.; Sheppard, C. L.; Siira, L.; Skoczyńska, A.; Sloan, M.; Slotved, H.-C.; Smith, A. J.; Song, J. Y.; Taha, M.-K.; Toropainen, M.; Tsang, D.; Vainio, A.; van Sorge, N. M.; Varon, E.; Vlach, J.; Vogel, U.; Vohrnova, S.; von Gottberg, A.; Zanella, R. C.; Zhou, F. Changes in the Incidence of Invasive Disease Due to Streptococcus Pneumoniae, Haemophilus Influenzae, and Neisseria Meningitidis during the COVID-19 Pandemic in 26 Countries and Territories in the Invasive Respiratory Infection Surveillance Initiative: A Prospective Analysis of Surveillance Data. Lancet Digit Health 2021, 3 (6), e360–e370. https://doi.org/10.1016/S2589-7500(21)00077-7.

(10) Taubenberger, J. K.; Hultin, J. V.; Morens, D. M. Discovery and Characterization of the 1918 Pandemic Influenza Virus in Historical Context. Antivir Ther 2007, 12 (4 Pt B), 581–591.

(11) Heinz, E. The Return of Pfeiffer’s Bacillus: Rising Incidence of Ampicillin Resistance in Haemophilus Influenzae. Microb Genom 2018, 4 (9), e000214. https://doi.org/10.1099/mgen.0.000214.

(12) Verma, R.; Khanna, P.; Chawla, S.; Bairwa, M.; Prinja, S.; Rajput, M. Haemophilus Influenzae Type b (Hib) Vaccine: An Effective Control Strategy in India. Hum Vaccin 2011, 7 (11), 1158–1160. https://doi.org/10.4161/hv.7.11.17683.

(13) Haemophilus influenzae - PAHO/WHO | Pan American Health Organization. https://www.paho.org/en/topics/haemophilus-influenzae (accessed 2023-09-17).

(14) Scholz, H.; Noack, R. [Hemophilus influenzae infection and their prevention by vaccination]. Kinderarztl Prax 1993, 61 (6), 189–191.

(15) Hersi, K.; Gonzalez, F. J.; Kondamudi, N. P. Meningitis. In StatPearls; StatPearls Publishing: Treasure Island (FL), 2023.

(16) Guerra, A. M.; Waseem, M. Epiglottitis. In StatPearls; StatPearls Publishing: Treasure Island (FL), 2023.

(17) Torres, A.; Cilloniz, C.; Niederman, M. S.; Menéndez, R.; Chalmers, J. D.; Wunderink, R. G.; van der Poll, T. Pneumonia. Nat Rev Dis Primers 2021, 7 (1), 25. https://doi.org/10.1038/s41572-021-00259-0.

(18) Rowley, A. H.; Wald, E. R. The Incubation Period Necessary for Detection of Bacteremia in Immunocompetent Children with Fever. Implications for the Clinician. Clin Pediatr (Phila) 1986, 25 (10), 485–489. https://doi.org/10.1177/000992288602501001.

(19) Jr, G. Hib Vaccines: Their Impact on Haemophilus Influenzae Type b Disease. The Journal of infectious diseases 2021, 224 (12 Suppl 2). https://doi.org/10.1093/infdis/jiaa537.

(20) Hunt, B. C.; Xu, X.; Gaggar, A.; Swords, W. E. Nontypeable Haemophilus Influenzae Redox Recycling of Protein Thiols Promotes Resistance to Oxidative Killing and Bacterial Survival in Biofilms in a Smoke-Related Infection Model. mSphere 2022, 7 (1), e0084721. https://doi.org/10.1128/msphere.00847-21.

(21) Wen, S.; Feng, D.; Chen, D.; Yang, L.; Xu, Z. Molecular Epidemiology and Evolution of Haemophilus Influenzae. Infect Genet Evol 2020, 80, 104205. https://doi.org/10.1016/j.meegid.2020.104205.

(22) Saleh, A.; Qamar, S.; Tekin, A.; Singh, R.; Kashyap, R. Vaccine Development Throughout History. Cureus 13 (7), e16635. https://doi.org/10.7759/cureus.16635.

(23) About Hib Vaccine (Haemophilus Influenzae Type b Vaccine) | CDC. https://www.cdc.gov/vaccines/vpd/hib/hcp/about-vaccine.html (accessed 2023-08-08).

(24) Goldblatt, D. Conjugate Vaccines. Clin Exp Immunol 2000, 119 (1), 1–3. https://doi.org/10.1046/j.1365-2249.2000.01109.x.

(25) Kadry, N. A.; Porsch, E. A.; Shen, H.; St. Geme, J. W. Immunization with HMW1 and HMW2 Adhesins Protects against Colonization by Heterologous Strains of Nontypeable Haemophilus Influenzae. Proc Natl Acad Sci U S A 2021, 118 (32), e2019923118. https://doi.org/10.1073/pnas.2019923118.

(26) Cerquetti, M.; Giufrè, M. Why We Need a Vaccine for Non-Typeable Haemophilus Influenzae. Hum Vaccin Immunother 2016, 12 (9), 2357–2361. https://doi.org/10.1080/21645515.2016.1174354.

(27) Behrouzi, A.; Vaziri, F.; Rahimi-Jamnani, F.; Afrough, P.; Rahbar, M.; Satarian, F.; Siadat, S. D. Vaccine Candidates against Nontypeable Haemophilus Influenzae: A Review. Iran Biomed J 2017, 21 (2), 69–76. https://doi.org/10.18869/acadpub.ibj.21.2.69.

(28) Mu, X.-Q.; Egelman, E. H.; Bullitt, E. Structure and Function of Hib Pili from Haemophilus Influenzae Type b. J Bacteriol 2002, 184 (17), 4868–4874. https://doi.org/10.1128/JB.184.17.4868-4874.2002.

(29) Commissioner, O. of the. The Drug Development Process. FDA. https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-development-process (accessed 2023-09-19).

(30) How Vaccines are Developed and Approved for Use | CDC. https://www.cdc.gov/vaccines/basics/test-approve.html (accessed 2023-09-19).

(31) Pinkbook: Haemophilus influenzae (Hib) | CDC. https://www.cdc.gov/vaccines/pubs/pinkbook/hib.html (accessed 2023-04-07).

(32) Cress, B. F.; Englaender, J. A.; He, W.; Kasper, D.; Linhardt, R. J.; Koffas, M. A. G. Masquerading Microbial Pathogens: Capsular Polysaccharides Mimic Host-Tissue Molecules. FEMS Microbiol Rev 2014, 38 (4), 660–697. https://doi.org/10.1111/1574-6976.12056.

(33) Haemophilus b Conjugate Vaccines for Prevention of Haemophilus influenzae Type b Disease Among Infants and Children Two Months of Age and Older Recommendations of the ACIP. https://www.cdc.gov/mmwr/preview/mmwrhtml/00041736.htm (accessed 2023-09-20).

(34) Medical Definition of Tetanus. RxList. https://www.rxlist.com/tetanus/definition.htm (accessed 2023-09-20).

(35) Medical Definition of Clostridium. RxList. https://www.rxlist.com/clostridium/definition.htm (accessed 2023-09-20).

(36) ActHIB (Haemophilus b Conjugate Vaccine): Uses, Dosage, Side Effects, Interactions, Warning. RxList. https://www.rxlist.com/acthib-drug.htm (accessed 2023-09-20).

(37) Centers for Disease Control and Prevention (CDC). FDA Approval of a Haemophilus b Conjugate Vaccine Combined by Reconstitution with an Acellular Pertussis Vaccine. MMWR Morb Mortal Wkly Rep 1996, 45 (45), 993–995.

(38) ActHIB (Haemophilus b Conjugate Vaccine): Uses, Dosage, Side Effects, Interactions, Warning. RxList. https://www.rxlist.com/acthib-drug.htm (accessed 2023-09-20).

(39) Research, C. for B. E. and. ActHIB. FDA 2022.

(40) Siegrist, C.-A. Mechanisms Underlying Adverse Reactions to Vaccines. J Comp Pathol 2007, 137 Suppl 1, S46-50. https://doi.org/10.1016/j.jcpa.2007.04.012.

(41) Hib/MenC vaccine side effects. nhs.uk. https://www.nhs.uk/conditions/vaccinations/hib-men-c-booster-side-effects/ (accessed 2023-09-20).

(42) Fortunato, F.; Martinelli, D.; Lopalco, P. L.; Prato, R. Safety Evaluation of the DTaP5-IPV-Hib-HepB Vaccine: A Review. Expert Opin Drug Saf 2022, 21 (3), 295–302. https://doi.org/10.1080/14740338.2022.2007882.

(43) Moro, P. L.; Jankosky, C.; Menschik, D.; Lewis, P.; Duffy, J.; Stewart, B.; Shimabukuro, T. T. Adverse Events Following Haemophilus Influenzae Type b (Hib) Vaccines in the Vaccine Adverse Event Reporting System (VAERS), 1990-2013. J Pediatr 2015, 166 (4), 992–997. https://doi.org/10.1016/j.jpeds.2014.12.014.

(44) Nix, E. B.; Hawdon, N.; Gravelle, S.; Biman, B.; Brigden, M.; Malik, S.; McCready, W.; Ferroni, G.; Ulanova, M. Risk of Invasive Haemophilus Influenzae Type b (Hib) Disease in Adults with Secondary Immunodeficiency in the Post-Hib Vaccine Era. Clin Vaccine Immunol 2012, 19 (5), 766–771. https://doi.org/10.1128/CVI.05675-11.

(45) Sharma, A.; Kaplan, W. A.; Chokshi, M.; Hasan Farooqui, H.; Zodpey, S. P. Implications of Private Sector Hib Vaccine Coverage for the Introduction of Public Sector Hib-Containing Pentavalent Vaccine in India: Evidence from Retrospective Time Series Data. BMJ Open 2015, 5 (2), e007038. https://doi.org/10.1136/bmjopen-2014-007038.

(46) Akkoyunlu, M.; Melhus, A.; Capiau, C.; van Opstal, O.; Forsgren, A. The Acylated Form of Protein D of Haemophilus Influenzae Is More Immunogenic than the Nonacylated Form and Elicits an Adjuvant Effect When It Is Used as a Carrier Conjugated to Polyribosyl Ribitol Phosphate. Infect Immun 1997, 65 (12), 5010–5016.

(47) Dhillon, S.; Keam, S. J. DTaP-IPV/Hib Vaccine (Pentacel). Paediatr Drugs 2008, 10 (6), 405–416. https://doi.org/10.2165/0148581-200810060-00008.

(48) Pentacel (Tetanus Toxoid Conjugate): Uses, Dosage, Side Effects, Interactions, Warning. RxList. https://www.rxlist.com/pentacel-drug.htm (accessed 2023-09-20).

(49) Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, and Haemophilus b Conjugate Vaccine and Guidance for Use in Infants and Children. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5739a5.htm (accessed 2023-09-20).

(50) Federal Advisory Committee Votes to Include Newly Licensed Pentacel® Vaccine in Vaccines for Children Program. https://www.news.sanofi.us/press-releases?item=137050 (accessed 2023-08-08).

(51) Dhillon, S.; Keam, S. J. DTaP-IPV/Hib Vaccine (Pentacel). Paediatr Drugs 2008, 10 (6), 405–416. https://doi.org/10.2165/0148581-200810060-00008.

(52) Wen, S., Feng, D., Chen, D., Yang, L., & Xu, Z. (2020). Molecular epidemiology and evolution of Haemophilus influenzae. Infection, Genetics and Evolution, 80, 104205. https://doi.org/10.1016/j.meegid.2020.104205

(53) Research C for BE and. ActHIB. FDA. Published online October 14, 2022. Accessed July 22, 2024. https://www.fda.gov/vaccines-blood-biologics/vaccines/acthib

(54) Research C for BE and. VAXELIS. FDA. Published online April 13, 2023. Accessed July 22, 2024. https://www.fda.gov/vaccines-blood-biologics/vaxelis

(55) Research C for BE and. Pentacel. FDA. Published online February 28, 2023. Accessed July 22, 2024. https://www.fda.gov/vaccines-blood-biologics/vaccines/pentacel

(56) Behrouzi A, Vaziri F, Rahimi-Jamnani F, et al. Vaccine Candidates against Nontypeable Haemophilus influenzae: a Review. Iran Biomed J. 2017;21(2):69-76. doi:10.18869/acadpub.ibj.21.2.69

Haemophilus Influenzae type b Vaccines: Current Trends and Future Outlook

The evaluation of the efficacy of Haemophilus influenzae type b vaccines and the potential strategies for Nontypeable Haemophilus influenzae vaccines.

##article.authors##

DOI:

Keywords:

Abstract

References

Additional Files

Posted

Categories

License